GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...

GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...

GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy has been approved in Malaysia for respiratory ...

Spread of the virus is seasonal, with activity often picking up in the fall after kids go back to school. Activity usually ...

Emmetrope Ophthalmics, LLC ("Emmecell"), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of serious eye diseases, today ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

The most frequently reported adverse reactions were injection site pain ... pharmacies and ultimately help to get ahead of RSV and shingles.” Arexvy is indicated for active immunization for ...

The company studied co-administration of its RSV vaccine Arexvy and Shingrix in a phase ... to vaccine administration such as pain at the injection site, fatigue and muscle pain.

Adults aged 60 and over with underlying co-morbidities are at high risk of developing severe infections from RSV Vaccine showed ... solicited adverse events were injection site pain, fatigue ...